Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02TGD
|
|||
| Former ID |
DCL000897
|
|||
| Drug Name |
Netoglitazone
|
|||
| Synonyms |
Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-alcoholic fatty liver disease [ICD-11: DB92; ICD-10: K76.0; ICD-9: 571.8] | Phase 2 | [1], [2] | |
| Company |
Mitsubishi Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H16FNO3S
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F
|
|||
| InChI |
1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25)
|
|||
| InChIKey |
PKWDZWYVIHVNKS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 161600-01-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10266079, 12014903, 14804654, 30409351, 47206874, 53789988, 56314529, 57399414, 78102491, 103302827, 104438295, 126455542, 127315825, 127315826, 127315827, 127315828, 127315829, 127334948, 127334949, 127334950, 127334951, 127334952, 134224278, 134339349, 134339958, 135178649, 135650709, 137063230, 140097400, 143170090, 162222887, 176225523, 179150029, 215780839, 223704978, 223908693, 226509499, 252450244, 252543600
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2707). | |||
| REF 2 | Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. | |||
| REF 3 | Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.